tmem160 Antibody

What is TMEM160 and what cellular compartments does it localize to?

TMEM160 (transmembrane protein 160) is a mitochondrial protein with a canonical length of 188 amino acid residues and a molecular mass of approximately 19.7 kDa in humans. Research has definitively established that TMEM160 localizes to the mitochondrial inner membrane . This protein belongs to the TMEM160 family, with orthologs identified across multiple species including mouse, rat, bovine, zebrafish, and chimpanzee .

To confirm TMEM160's mitochondrial localization, researchers typically employ co-localization studies using Mito Tracker Red followed by immunostaining with anti-TMEM160 or anti-tag antibodies. Fluorescence microscopy reveals that TMEM160 signal patterns closely match mitochondrial markers, confirming its mitochondrial compartmentalization .

What applications are most suitable for TMEM160 antibodies?

TMEM160 antibodies have been validated for multiple research applications, with Western blot (WB) being the most commonly utilized technique. Additional validated applications include:

When conducting IHC with TMEM160 antibodies, antigen retrieval with TE buffer (pH 9.0) is recommended, though citrate buffer (pH 6.0) may serve as an alternative .

What is the expected molecular weight of TMEM160 in experimental detection?

While the calculated molecular weight of TMEM160 is 20 kDa (from its 188 amino acid sequence), researchers should note that the observed molecular weight in experimental conditions typically ranges between 15-20 kDa . This discrepancy between theoretical and observed weights is not uncommon for small transmembrane proteins and may reflect:

• Post-translational modifications

• Protein processing during mitochondrial import

• The hydrophobic nature of transmembrane domains affecting mobility in SDS-PAGE

• Sample preparation conditions

When validating TMEM160 antibody specificity, researchers should determine whether the detected band corresponds to the expected 15-20 kDa range. Additionally, confirmation using TMEM160 knockout/knockdown controls is recommended to ensure specificity .

How should researchers optimize TMEM160 antibody detection in Western blots?

For optimal detection of TMEM160 in Western blot applications, researchers should consider the following methodological recommendations:

• Sample preparation: Use RIPA buffer supplemented with protease inhibitors for efficient extraction of this mitochondrial transmembrane protein

• Protein loading: 20-40 μg of total protein is typically sufficient for detection

• Antibody dilution: Use 1:500-1:1000 dilution of primary antibody (optimize based on antibody source)

• Membrane type: PVDF membranes generally provide better results than nitrocellulose for this hydrophobic protein

• Blocking solution: 5% non-fat milk in TBST is recommended to minimize background

• Incubation time: Overnight incubation at 4°C with primary antibody often yields optimal results

• Controls: Include positive control samples (HEK-293 cell lysate has been validated)

• Validation method: Confirm specificity using TMEM160 knockdown/knockout samples as negative controls

The protein can be detected at approximately 15-20 kDa, and researchers should be attentive to this size range when analyzing their Western blot results .

What techniques are available for studying TMEM160's interactions with other proteins?

Several experimental approaches have been validated for investigating TMEM160's protein-protein interactions:

• Co-immunoprecipitation (Co-IP): Successfully employed to detect interactions between TMEM160 and PD-L1 in colorectal cancer cell lines (DLD1 and HCT116) . The protocol utilizes Protein A/G immunoprecipitation followed by Western blotting.

• GST pull-down assays: Effective for confirming direct protein-protein interactions with TMEM160 .

• Proximity ligation assays: Can be used to visualize protein interactions in situ within cells.

• Subcellular fractionation: Useful for studying TMEM160's association with mitochondrial membrane components. Alkali extraction with sodium carbonate (pH 11.5) has been employed to demonstrate TMEM160's membrane integration properties .

For investigators examining TMEM160's role in protein stability, methods such as the cycloheximide (CHX) half-life assay (40 μg/ml CHX treatment for 0, 2, 4, and 8 hours) and the MG132 rescue assay (10 μM MG132 for 6 hours) have provided valuable insights into TMEM160's impact on PD-L1 stability .

How does TMEM160 influence mitochondrial function and reactive oxygen species generation?

Contrary to earlier studies suggesting TMEM160 loss does not affect mitochondrial function, recent research demonstrates that TMEM160 depletion significantly impacts mitochondrial homeostasis and cellular stress responses . Key experimental findings include:

• Increased ROS generation: TMEM160 knockdown results in significantly elevated reactive oxygen species levels, suggesting a role in maintaining mitochondrial redox balance .

• Mitochondrial unfolded protein response (UPRmt) activation: TMEM160 depletion upregulates multiple UPRmt markers:

  • Mitochondrial chaperone HSPD1

  • Key transcription factors (ATF4, ATF5, DDIT3)

  • Mitochondrial protein import receptors (TOMM22, TOMM20)

• Oxidative stress management: TMEM160 knockdown cells show altered patterns of 4-hydroxynonenal (4-HNE)-modified proteins, indicating enhanced degradation of oxidatively damaged proteins .

• Persistent UPRmt activation: Interestingly, even after ROS was scavenged with N-acetylcysteine (NAC), UPRmt markers remained upregulated, suggesting TMEM160 depletion induces UPRmt independently of subsequent ROS detoxification .

These findings suggest TMEM160 functions to suppress ROS generation and stabilize certain mitochondrial proteins, with important implications for mitochondrial stress response pathways.

What mechanisms explain TMEM160's role in cancer progression and immune evasion?

Recent research has uncovered a novel function of TMEM160 in promoting tumor immune evasion, particularly in colorectal cancer (CRC). The molecular mechanisms involve:

• PD-L1 stabilization: TMEM160 interacts directly with programmed death-ligand 1 (PD-L1) and inhibits its ubiquitination-dependent degradation .

• Competition with SPOP: TMEM160 competes with Speckle-type POZ protein (SPOP) for binding to PD-L1, thereby interfering with SPOP-mediated PD-L1 degradation .

• Impact on cancer cell phenotypes: TMEM160 depletion significantly inhibits:

  • Proliferation

  • Invasion

  • Metastasis

  • Clonogenicity

  • Radioresistance of CRC cells

  • While enhancing CD8+ T cell cytotoxicity against tumor cells

• Clinical correlations: In CRC patient samples, TMEM160 expression positively correlates with PD-L1 expression and negatively correlates with CD8A expression. Higher TMEM160 expression is associated with worse prognosis .

These findings suggest TMEM160 could serve as a potential therapeutic target for enhancing anti-tumor immunity and improving radiotherapy outcomes in colorectal cancer patients.

How can researchers effectively design TMEM160 knockdown/knockout experiments?

For successful TMEM160 functional studies through gene silencing or knockout, researchers should consider these methodological recommendations:

• RNA interference approach:

  • siRNA transfection has been successfully used in various cell lines

  • Effective TMEM160 knockdown can be achieved within 48-72 hours post-transfection

  • Validation of knockdown efficiency should be performed using both qRT-PCR and Western blot

• CRISPR-Cas9 knockout strategy:

  • Target guide RNAs to early exons of TMEM160

  • Validate knockout through genomic sequencing

  • Confirm protein loss using validated TMEM160 antibodies

  • Establish stable knockout cell lines for long-term experiments

• Rescue experiments:

  • Express siRNA-resistant TMEM160 constructs to confirm phenotype specificity

  • Use TMEM160-Myc-DYKDDDDK tagged constructs that have been validated for proper mitochondrial localization

• Functional readouts:

  • ROS measurement using fluorescent probes

  • Mitochondrial membrane potential assessment

  • UPRmt markers by Western blot or qRT-PCR

  • For cancer studies: proliferation, invasion, and T cell co-culture assays

• Controls and validation:

  • Include non-targeting siRNA controls

  • Use multiple independent siRNA sequences to rule out off-target effects

  • Validate knockdown at both mRNA and protein levels

  • Perform rescue experiments to confirm specificity

What approaches should be used to study TMEM160's subcellular localization?

To accurately determine TMEM160's submitochondrial localization, researchers should employ multiple complementary techniques:

• Immunofluorescence microscopy:

  • Co-staining with established mitochondrial markers (e.g., MitoTracker Red)

  • High-resolution confocal microscopy to visualize submitochondrial structures

  • Super-resolution microscopy for precise localization within mitochondrial compartments

  • Protocol example: Culture cells on coverslips, treat with MitoTracker Red, fix with 4% paraformaldehyde, permeabilize with 0.1% Triton X-100, and immunostain with anti-TMEM160 antibody

• Biochemical fractionation:

  • Differential centrifugation to isolate mitochondria

  • Submitochondrial fractionation to separate outer membrane, inner membrane, and matrix

  • Alkaline extraction with sodium carbonate (pH 11.5) to distinguish between integral membrane proteins and membrane-associated proteins

• Protease protection assays:

  • Treat intact or selectively permeabilized mitochondria with proteases

  • Analyze TMEM160 degradation patterns to determine topology

• Electron microscopy:

  • Immunogold labeling of TMEM160 for precise submitochondrial localization

  • Analysis of TMEM160 distribution across mitochondrial compartments

Using these combined approaches, researchers have confirmed that TMEM160 is an integral protein of the mitochondrial inner membrane, resistant to alkaline extraction (similar to known integral membrane proteins like MTCO1 and VDAC1) .

How should researchers interpret contradictory findings regarding TMEM160's function?

The scientific literature contains some contradictory findings regarding TMEM160's impact on cellular functions. To navigate these discrepancies, researchers should consider:

How should researchers quantify TMEM160 expression in clinical samples?

For accurate quantification of TMEM160 expression in clinical samples, researchers should follow these validated approaches:

• Immunohistochemistry scoring:

  • Utilize a comprehensive H-score system that incorporates both staining intensity and percentage of positive cells

  • Staining intensity categories: negative (-), weak (+), intermediate (++), strong (+++)

  • Positive cell density scoring: 0% = 0, 1-25% = 1, 26-50% = 2, 51-75% = 3, >76% = 4

  • Calculate H-score = (% of staining positive cells)(0-4) × (staining intensity)(0-3)

  • Classify samples as TMEM160-low (H-score 0-4) or TMEM160-high (H-score 5-12)

• Western blot quantification:

  • Normalize TMEM160 band intensity to loading controls (β-actin, GAPDH)

  • Use at least three biological replicates

  • Employ image analysis software for densitometry

• RNA expression analysis:

  • qRT-PCR with validated primers and appropriate reference genes

  • RNA-seq with proper normalization

• Statistical considerations:

  • Use non-parametric tests for IHC scoring data

  • Apply appropriate multivariate analyses to control for confounding factors

  • Correlate TMEM160 expression with other relevant markers (e.g., PD-L1, CD8A)

Researchers should be aware that TMEM160 expression patterns may vary across different tissue types, and proper controls should be included to account for tissue-specific variation.

What are the experimental considerations for studying TMEM160's impact on protein stability?

To investigate TMEM160's role in regulating protein stability (such as PD-L1), researchers should employ these validated experimental approaches:

• Cycloheximide (CHX) chase assay:

  • Treat cells with CHX at 40 μg/ml final concentration

  • Harvest cells at multiple timepoints (0, 2, 4, and 8 hours)

  • Compare protein half-life between control and TMEM160-modified cells

  • This approach has successfully demonstrated TMEM160's effect on PD-L1 stability

• Proteasome inhibition rescue experiments:

  • Treat TMEM160-depleted cells with MG132 (10 μM for 6 hours)

  • Assess whether proteasome inhibition rescues reduced protein levels

  • This method can determine if TMEM160's effects are proteasome-dependent

• Ubiquitination assays:

  • Immunoprecipitate the protein of interest (e.g., PD-L1)

  • Probe for ubiquitin by Western blot

  • Compare ubiquitination levels between control and TMEM160-modified cells

  • This approach revealed TMEM160's role in preventing PD-L1 ubiquitination

• Competitive binding studies:

  • Co-immunoprecipitation with varying levels of competing proteins

  • GST pull-down assays with purified components

  • These methods demonstrated TMEM160's competition with SPOP for PD-L1 binding

• Domain mapping experiments:

  • Generate truncation mutants to identify interaction domains

  • Site-directed mutagenesis of key residues

  • These approaches can define the specific regions mediating protein-protein interactions

By combining these methodologies, researchers can comprehensively characterize TMEM160's role in regulating protein stability through modulation of ubiquitination-dependent degradation pathways.

What controls are essential for validating TMEM160 antibody specificity?

To ensure the highest level of experimental rigor when working with TMEM160 antibodies, researchers should implement the following validation controls:

• Genetic depletion controls:

  • TMEM160 knockdown using validated siRNA sequences

  • CRISPR-Cas9 knockout cell lines

  • These negative controls should show significantly reduced or absent signal

• Overexpression validation:

  • TMEM160 overexpression constructs (e.g., TMEM160-Myc-DYKDDDDK)

  • Dual detection with anti-tag and anti-TMEM160 antibodies

  • This approach confirmed the specificity of anti-TMEM160 antibodies in published studies

• Peptide competition:

  • Pre-incubate antibody with immunizing peptide

  • Signal should be substantially reduced or eliminated

• Multiple antibody validation:

  • Use antibodies raised against different epitopes

  • Compare detection patterns across applications

• Application-specific controls:

  • For Western blot: Full-length blot showing single band at expected molecular weight (15-20 kDa)

  • For IHC: Include positive control tissues (human intrahepatic cholangiocarcinoma)

  • For immunofluorescence: Co-localization with established mitochondrial markers

• Species validation:

  • Test cross-reactivity with TMEM160 orthologs in relevant experimental models

  • Antibodies may show different specificities across human, mouse, rat and other species

Implementation of these comprehensive control strategies ensures that experimental results truly reflect TMEM160 biology rather than antibody artifacts.

How can researchers integrate TMEM160 studies with broader mitochondrial and cancer biology?

To place TMEM160 research in a broader biological context, investigators should consider these integrative approaches:

• Mitochondrial stress response pathway analysis:

  • Examine TMEM160's relationship with established UPRmt factors

  • Connect TMEM160 function to mitochondrial quality control mechanisms

  • Investigate interplay with mitochondrial proteostasis networks

• Cancer immunology integration:

  • Study TMEM160 in relation to other immune checkpoint regulators

  • Analyze TMEM160 expression across cancer immune subtypes

  • Investigate potential therapeutic targeting strategies

• Multi-omics approaches:

  • Combine proteomics, transcriptomics, and metabolomics data

  • Identify broader pathway alterations following TMEM160 modulation

  • Map TMEM160-dependent interaction networks

• Translational research considerations:

  • Evaluate TMEM160 as a potential biomarker for cancer prognosis

  • Assess its utility in predicting response to immunotherapy

  • Consider it as a therapeutic target based on its dual roles in mitochondrial function and immune regulation

• Evolutionary perspective:

  • Compare TMEM160 function across species (human, mouse, rat, bovine, zebrafish, chimpanzee)

  • Study conservation of interacting partners and functional domains

By connecting TMEM160 research to these broader biological contexts, investigators can develop more comprehensive models of its functions and potential clinical applications.

How does TMEM160 expression correlate with clinical outcomes in cancer patients?

Clinical studies have revealed significant associations between TMEM160 expression and patient outcomes:

• Prognostic significance:

  • High TMEM160 expression is associated with worse prognosis in colorectal cancer patients

  • TMEM160 expression positively correlates with PD-L1 levels and negatively correlates with CD8A expression in clinical samples

• Scoring methodology:

  • Researchers quantify TMEM160 expression using the H-score system

  • H-score calculation: (% of staining positive cells)(0-4) × (staining intensity)(0-3)

  • Samples are categorized as TMEM160-low (H-score 0-4) or TMEM160-high (H-score 5-12)

• Tumor microenvironment impact:

  • TMEM160's relationship with PD-L1 suggests its involvement in tumor immune evasion

  • Negative correlation with CD8A indicates potential suppression of cytotoxic T cell infiltration

• Therapeutic implications:

  • TMEM160 may serve as a target for enhancing immunotherapy response

  • Its role in radioresistance suggests potential for improving radiation therapy outcomes

• Biomarker potential:

  • TMEM160 could potentially serve as a prognostic or predictive biomarker

  • Further validation in larger patient cohorts is warranted

These clinical correlations highlight TMEM160's potential importance in cancer biology and patient stratification, suggesting future directions for both basic and translational research.

What experimental models are most appropriate for studying TMEM160 function?

Researchers have successfully employed various experimental systems to study TMEM160 function:

• Cell line models:

  • HeLa cells for basic mitochondrial studies

  • HEK-293 cells for protein expression and antibody validation

  • Colorectal cancer cell lines (DLD1, HCT116, SW480) for cancer biology studies

• Animal models:

  • Immune-deficient mouse models for basic tumor growth studies

  • Immune-competent BALB/c mice for studying tumor-immune interactions

  • Significantly reduced tumor growth observed in TMEM160-depleted xenografts

• Patient-derived samples:

  • Human intrahepatic cholangiocarcinoma tissue for IHC validation

  • Colorectal cancer tissues for correlation between TMEM160, PD-L1, and CD8A expression

• Experimental approaches by research focus:

  • Mitochondrial studies: Cell fractionation, ROS measurements, stress response assays

  • Cancer biology: Proliferation, invasion, metastasis, and clonogenicity assays

  • Immune function: CD8+ T cell cytotoxicity assays, immune infiltration analysis

When selecting experimental models, researchers should consider the specific aspect of TMEM160 biology under investigation and choose systems that best recapitulate the relevant physiological or pathological context.

What future research directions may advance our understanding of TMEM160 function?

Several promising research directions could significantly expand our understanding of TMEM160 biology:

• Structural studies:

  • Determine the three-dimensional structure of TMEM160

  • Map interaction interfaces with binding partners

  • Identify potential druggable pockets

• Comprehensive interactome mapping:

  • Identify the complete set of TMEM160 protein interactions

  • Determine context-specific interaction changes

  • Connect to broader mitochondrial and cellular networks

• Tissue-specific functions:

  • Compare TMEM160 roles across different tissue types

  • Investigate tissue-specific interaction partners

  • Develop conditional knockout models for in vivo studies

• Therapeutic targeting strategies:

  • Develop small molecule inhibitors of TMEM160

  • Evaluate TMEM160 inhibition in combination with immunotherapy

  • Assess potential for enhancing radiotherapy response

• Biomarker development:

  • Validate TMEM160 as a prognostic or predictive biomarker

  • Develop standardized measurement protocols

  • Conduct large-scale clinical correlation studies

• Integration with mitochondrial biology:

  • Further characterize TMEM160's role in mitochondrial stress responses

  • Investigate its contribution to mitochondrial dynamics and quality control

  • Explore potential metabolic functions

These research directions promise to advance both our fundamental understanding of TMEM160 biology and its potential clinical applications, particularly in cancer treatment.

How should researchers optimize immunohistochemistry protocols for TMEM160 detection?

For optimal TMEM160 detection in tissue sections, researchers should implement these technical recommendations:

• Antigen retrieval optimization:

  • Primary recommendation: TE buffer pH 9.0

  • Alternative approach: Citrate buffer pH 6.0

  • Optimization may be required for different tissue types

• Antibody dilution:

  • Recommended range: 1:50-1:500

  • Titration experiments should be performed for each new tissue type

  • Optimal dilution may vary by fixation method and tissue source

• Blocking conditions:

  • 5-10% normal serum matching the species of the secondary antibody

  • Addition of 0.1-0.3% Triton X-100 for improved penetration

  • BSA (1-3%) may reduce non-specific binding

• Signal amplification options:

  • Standard ABC (avidin-biotin complex) method

  • Polymer-based detection systems for enhanced sensitivity

  • Tyramide signal amplification for low-abundance targets

• Counterstaining considerations:

  • Hematoxylin provides good nuclear contrast

  • Avoid overstaining which may mask specific TMEM160 signal

• Validation and controls:

  • Include positive control tissues (human intrahepatic cholangiocarcinoma)

  • Run isotype control antibodies at matching concentrations

  • Include TMEM160-depleted tissue/cell samples when available

Following these optimized protocols should enable reliable detection of TMEM160 in various tissue samples, supporting both basic research and potential clinical applications.

What troubleshooting approaches are recommended for TMEM160 protein detection challenges?

When encountering difficulties with TMEM160 detection, researchers should consider these systematic troubleshooting strategies:

• Western blot challenges:

  • No visible band: Try reducing primary antibody dilution (1:250), longer exposure times, or more sensitive detection methods

  • Multiple bands: Optimize blocking conditions, increase washing stringency, validate with knockout controls

  • Unexpected molecular weight: Consider post-translational modifications, use positive control samples (HEK-293 cells)

• Immunohistochemistry issues:

  • Weak signal: Optimize antigen retrieval (try pH 9.0 TE buffer), increase antibody concentration, extend incubation time

  • High background: More stringent blocking, reduce primary antibody concentration, increase wash duration

  • Non-specific staining: Validate with absorption controls, compare multiple TMEM160 antibodies

• Immunofluorescence problems:

  • Poor co-localization with mitochondria: Ensure proper fixation (4% paraformaldehyde), optimize permeabilization (0.1% Triton X-100)

  • Autofluorescence: Use Sudan Black B to quench, or employ spectral unmixing

  • Photobleaching: Use anti-fade mounting media, minimize exposure during imaging

• Co-immunoprecipitation difficulties:

  • Failed interaction detection: Try different lysis buffers, cross-linking approaches, or tag positions

  • High background: More stringent washes, pre-clear lysates, use monoclonal antibodies

  • Inconsistent results: Standardize cell confluence, lysis conditions, and protein amounts

By systematically addressing these common technical challenges, researchers can optimize TMEM160 detection across various experimental platforms and applications.